Melissa Hector-Greene

Melissa Hector-Greene

Auto-generated profile, based on publicly available information

Melissa Hector-Greene

Cardiovascular Division, Department of Medicine (P.M., J.J., M.H.-G., K.L.), Washington University School of Medicine, St. Louis, MO

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Cell
Verified
Journal Article
Closed access
ASAnna Sablina
Anna Sablina
WCWen Chen
Wen Chen
JAJason D. Arroyo
Jason D. Arroyo
LCLaura Corral
Laura Corral
MHMelissa Hector
Melissa Hector
WHWilliam C. Hahn
William C. Hahn

14 December 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAnna Sablina
Anna Sablina
MHMelissa Hector
Melissa Hector
NCNathalie Colpaert
Nathalie Colpaert
WHWilliam C. Hahn
William C. Hahn
The simian virus 40 small t (SV40ST) oncoprotein interacts with protein phosphatase 2A (PP2A), an abundantly expressed family of serine–threonine phosphatases. This interaction is essential for the transformation of human cells by SV40, and several PP2A subunits have been implicated as tumor suppressor genes. However, the pathways controlled by specific PP2A complexes involved in cell transformation remain incompletely understood. Using a comprehensive loss-of-function approach, we identified 4 PP2A regulatory subunits [B56α, B56γ, PR72/PR130, and PTPA (protein phosphatase 2A activator)], which when suppressed replaced the expression of SV40ST in human cell transformation. We found that manipulation of complexes containing PP2A B56α, B56γ, and PR72/PR130 activates the pathways regulated by c-Myc, Wnt, and PI3K (phosphoinositide 3-kinase)/Akt in a manner that depends on their specific phosphatase activity. In contrast, suppression of PTPA disrupts the assembly of PP2A heterotrimeric complexes, which leads to the activation of these same oncogenic pathways. These observations delineate the PP2A family members and pathways perturbed by SV40ST during human cell transformation. Cancer Res; 70(24); 10474–84. ©2010 AACR.

8 August 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
BHBrent A. Hanks
Brent A. Hanks
AHAlisha Holtzhausen
Alisha Holtzhausen
KEKatherine S. Evans
Katherine S. Evans
RJRebekah Jamieson
Rebekah Jamieson
PGPetra Gimpel
Petra Gimpel
GBGerard C. Blobe
Gerard C. Blobe
Cancers subvert the host immune system to facilitate disease progression. These evolved immunosuppressive mechanisms are also implicated in circumventing immunotherapeutic strategies. Emerging data indicate that local tumor-associated DC populations exhibit tolerogenic features by promoting Treg development; however, the mechanisms by which tumors manipulate DC and Treg function in the tumor microenvironment remain unclear. Type III TGF-β receptor (TGFBR3) and its shed extracellular domain (sTGFBR3) regulate TGF-β signaling and maintain epithelial homeostasis, with loss of TGFBR3 expression promoting progression early in breast cancer development. Using murine models of breast cancer and melanoma, we elucidated a tumor immunoevasion mechanism whereby loss of tumor-expressed TGFBR3/sTGFBR3 enhanced TGF-β signaling within locoregional DC populations and upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs and the CCL22 chemokine in myeloid DCs. Alterations in these DC populations mediated Treg infiltration and the suppression of antitumor immunity. Our findings provide mechanistic support for using TGF-β inhibitors to enhance the efficacy of tumor immunotherapy, indicate that sTGFBR3 levels could serve as a predictive immunotherapy biomarker, and expand the mechanisms by which TGFBR3 suppresses cancer progression to include effects on the tumor immune microenvironment.

1 April 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
PPPietri Puustinen
Pietri Puustinen
MJMelissa R. Junttila
Melissa R. Junttila
SVSari Vanhatupa
Sari Vanhatupa
ASAnna Sablina
Anna Sablina
MHMelissa E. Hector
Melissa E. Hector
Jukka WestermarckJukka Westermarck
Jukka Westermarck
Extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase pathway activity is regulated by the antagonist function of activating kinases and inactivating protein phosphatases. Sustained ERK pathway activity is commonly observed in human malignancies; however, the mechanisms by which the pathway is protected from phosphatase-mediated inactivation in the tumor tissue remain obscure. Here, we show that methylesterase PME-1–mediated inhibition of the protein phosphatase 2A promotes basal ERK pathway activity and is required for efficient growth factor response. Mechanistically, PME-1 is shown to support ERK pathway signaling upstream of Raf, but downstream of growth factor receptors and protein kinase C. In malignant gliomas, PME-1 expression levels correlate with both ERK activity and cell proliferation in vivo. Moreover, PME-1 expression significantly correlates with disease progression in human astrocytic gliomas (n = 222). Together, these observations identify PME-1 expression as one mechanism by which ERK pathway activity is maintained in cancer cells and suggest an important functional role for PME-1 in the disease progression of human astrocytic gliomas. [Cancer Res 2009;69(7):2870–7]

1 August 2025 in Circulation Research
Verified
Journal Article
Closed access
Pan MaPan Ma
Pan Ma
JJJesus Jimenez
Jesus Jimenez
AVAna Villanueva
Ana Villanueva
GWGuanhua Wu
Guanhua Wu
DBDiane Bender
Diane Bender
KLKORY J. LAVINE
KORY J. LAVINE